BioBrief covers the key biotech and pharma moves from Wednesday, April 29, 2026. Today’s episode focuses on late-stage obesity data, a survival-positive HER2 gastric cancer filing, Teva’s neuroscience acquisition, and Immunome’s desmoid tumor NDA.

1. Boehringer Ingelheim / Zealand Pharma — survodutide
   • Mechanism: Dual glucagon and GLP-1 receptor agonist
   • Indication: Obesity or overweight without type 2 diabetes
   • Stage: Phase 3
   • Key result: 16.6% body-weight loss at 76 weeks versus 3.2% on placebo in 725 adults
   • Why it matters: Survodutide now looks like a credible late-stage obesity contender, with full data expected at ADA in June.
2. BeOne Medicines / Jazz Pharmaceuticals — TEVIMBRA + ZIIHERA + chemotherapy
   • Mechanism: PD-1 antibody plus bispecific HER2 antibody plus chemotherapy ...